Track topics on Twitter Track topics that are important to you
Stereotaxis Inc (OTCQX:STSX) CEO David Leo Fischel tells Proactive Investors that the robotic technologies company that designs robotics instruments to treat heart arrhythmias and perform endovascular procedures, has posted record recurring revenue for 2018.
Fischel says despite investing more than $8 million in R&D last year, the company has achieved record recurring revenue of $27.8 million.NEXT ARTICLE
Cardiology is a specialty of internal medicine. Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...